ArticleCancer2008
Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy.
Article in Cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed.
- Clinical and magnetic resonance imaging features of soft tissue extraskeletal myxoid chondrosarcoma: A retrospective observational cohort study.Skeletal radiology · 2026Observational
- Extraskeletal Myxoid Chondrosarcoma Mimicking Myoepithelial Tumor.Case reports in pathology · 2026Article
- Article
- Ureteral stenosis due to extraskeletal chondroma: An exceptionally rare case report.Urology case reports · 2025Article
- From pathogenesis to the patient's bedside: a comprehensive review of extraskeletal myxoid chondrosarcoma.Journal of cancer research and clinical oncology · 2025Review
- The role of radiotherapy and chemotherapy in extraskeletal myxoid chondrosarcoma.Journal of orthopaedic surgery and research · 2025Article
- Article
- Microcystic/Reticular Schwannoma of the Skin: A Report of a Rare Case and Brief Literature Review.Cureus · 2025Article
- Aggressive Subtypes of Laryngeal Chondrosarcoma and their Clinical Behavior: A Systematic Review.Oncology and therapy · 2025Review
- Chondrosarcoma: New Molecular Insights, Challenges in Near-Patient Preclinical Modeling, and Therapeutic Approaches.International journal of molecular sciences · 2025Review
- Spontaneous regression of metastatic disease after palliative debulking surgery for heavily pre-treated extraskeletal myxoid chondrosarcoma: A case report.Rare tumors · 2025Article
- Extraskeletal Myxoid Chondrosarcoma of Floor of Mouth-A Rare Case Report and Review of Literature.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2024Article
- Juxta-articular extraskeletal myxoid chondrosarcoma mistaken for a benign cyst presenting with multiple lung metastases.Radiology case reports · 2024Article
- The Landscape of microRNAs in Bone Tumor: A Comprehensive Review in Recent Studies.MicroRNA (Shariqah, United Arab Emirates) · 2024Review
- Extraskeletal Myxoid Chondrosarcoma Identified in a Traumatic Fracture of the Toe: A Case Report.Journal of orthopaedic case reports · 2023Article
- Classification of Chondrosarcoma: From Characteristic to Challenging Imaging Findings.Cancers · 2023Review
- Chondrosarcoma of Ureter in an Elderly Patient: A Case Report.Medicina (Kaunas, Lithuania) · 2023Article
- Extraskeletal myxoid chondrosarcoma: p53 and Ki-67 offer prognostic value for clinical outcome - an immunohistochemical and molecular analysis of 31 cases.Virchows Archiv : an international journal of pathology · 2023Article
- Extraskeletal myxoid chondrosarcoma in the pelvis successfully treated with proton beam radiotherapy.BMJ case reports · 2023Article
- Whole genome sequencing for metastatic mutational burden in extraskeletal myxoid chondrosarcoma.Frontiers in molecular medicine · 2023Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundExtraskeletal myxoid chondrosarcoma (EMC) is a genetically distinct sarcoma with a propensity for local recurrence and metastasis despite an indolent course. To the authors' knowledge, there are limited data examining chemotherapy outcomes as a guide to therapeutic decisions for unresectable disease.
methodsThe clinical behavior and treatment responses of 87 patients with EMC who were seen at 2 institutions between 1975 and 2008 were examined.
resultsThe median age of the patients at the time of diagnosis was 49.5 years, with a male-to-female ratio of 2:1. For patients presenting without metastases, 37% developed local recurrence (median time of 3.3 years) and 26% developed distal recurrence (median time of 3.2 years). Approximately 13% of patients presented with metastases. The 5-year, 10-year, and 15-year overall survival rates were 82%, 65%, and 58%, respectively. Twenty-one patients received 32 evaluable courses of chemotherapy. No significant radiologic or clinical responses were noted. The median time to disease progression while receiving chemotherapy was 5.2 months. The best physician-assessed response to chemotherapy was stable disease for at least 6 months in 25% of patients, stable disease for <6 months in 41% of patients, and disease progression in 34% of patients. The estimated progression-free survival rates at 3 months, 4 months, 6 months, and 9 months were 69%, 65%, 40%, and 26%, respectively.
conclusionsThis retrospective review highlights the poor response rate to chemotherapy and emphasizes aggressive control of localized disease as the primary approach to management. Although there are biases inherent in retrospective analyses, these data provide a benchmark for time to disease progression for the study of new agents for the treatment of patients with this diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.